These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 36694524)

  • 1. Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Related Hospital Outcomes: A Cross-Sectional Study of US Hospitals.
    Kommuru S; Sagireddy S; Patel AM; Thoutam HR; Yasmeen S; Jarrad AA; Kaur G; Patel V
    Cureus; 2022 Dec; 14(12):e32821. PubMed ID: 36694524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of Left Ventricular Assist Device for Congestive Heart Failure: Inputs on Demographic and Hospital Characterization From Nationwide Inpatient Sample.
    Modi K; Pannu AK; Modi RJ; Shah SD; Bhandari R; Pereira KN; Kubra KT; Raval MR; Ajibawo T
    Cureus; 2021 Jul; 13(7):e16094. PubMed ID: 34367750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson S; Horvath Walsh LE; Wade RL
    Adv Ther; 2019 Aug; 36(8):1922-1935. PubMed ID: 31222713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Hospitalized Adults with Opioid Use Disorder in the United States: Nationwide Inpatient Sample.
    Alemu BT; Olayinka O; Martin BC
    Pain Physician; 2021 Aug; 24(5):327-334. PubMed ID: 34323434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discharge dispositions, complications, and costs of hospitalization in spinal cord tumor surgery: analysis of data from the United States Nationwide Inpatient Sample, 2003-2010.
    Sharma M; Sonig A; Ambekar S; Nanda A
    J Neurosurg Spine; 2014 Feb; 20(2):125-41. PubMed ID: 24286530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
    Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence, economic burden, and treatment of acute respiratory tract infection in hematopoietic stem cell transplantation recipients using real world data in Japan: a retrospective claims data analysis.
    Wattanakamolkul K; Nakayama Y
    J Med Econ; 2022; 25(1):870-879. PubMed ID: 35703058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation.
    Preussler JM; Meyer CL; Mau LW; Majhail NS; Denzen EM; Edsall KC; Farnia SH; Saber W; Burns LJ; Vanness DJ
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):1021-1028. PubMed ID: 28263920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation.
    Yu J; Parasuraman S; Shah A; Weisdorf D
    Curr Med Res Opin; 2019 Jun; 35(6):983-988. PubMed ID: 30461314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia.
    Silla L; Dulley F; Saboya R; Kerbauy F; de Moraes Arantes A; Pezzi A; Gross LG; Paton E; Hamerschlak N
    Eur J Haematol; 2017 Feb; 98(2):177-183. PubMed ID: 27621140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome and late effects among acute myeloid leukemia survivors: a nationwide population-based study.
    Chang KH; Hwang WL; Muo CH; Hsu CY; Teng CJ
    Support Care Cancer; 2016 Dec; 24(12):4993-5000. PubMed ID: 27502072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2020 Dec; 99(12):2911-2925. PubMed ID: 33000361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation.
    Vasudevan Nampoothiri R; Chen S; Pasic I; Al-Shaibani Z; Lam W; Michelis FV; Kim DDH; Viswabandya A; Gerbitz A; Lipton JH; Kumar R; Mattsson J; Law AD
    Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):134-140. PubMed ID: 33049225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
    Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia.
    Ciftciler R; Demiroglu H; Buyukasık Y; Aladag E; Aksu S; Haznedaroglu IC; Sayınalp N; Ozcebe O; Malkan UY; Goker H
    Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):177-182. PubMed ID: 30616990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.
    Vaughn JE; Othus M; Powell MA; Gardner KM; Rizzuto DL; Hendrie PC; Becker PS; Pottinger PS; Estey EH; Walter RB
    JAMA Oncol; 2015 Nov; 1(8):1120-7. PubMed ID: 26355382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement.
    Aoki J; Ishiyama K; Taniguchi S; Fukuda T; Ohashi K; Ogawa H; Kanamori H; Eto T; Iwato K; Sakamaki H; Morishima Y; Nagamura T; Atsuta Y; Takami A
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):2029-33. PubMed ID: 25196856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.
    Ganguly S; Cortes JE; Krämer A; Levis MJ; Martinelli G; Perl AE; Russell NH; Arunachalam M; Santos CD; Gammon G; Lesegretain A; Mires DE; Pham H; Wang Y; Khaled SK
    Transplant Cell Ther; 2021 Feb; 27(2):153-162. PubMed ID: 33017662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution.
    Lin CH; Chen TC; Shih YH; Chou CW; Hsu CY; Li PH; Teng CJ
    J Int Med Res; 2022 Feb; 50(2):3000605221078466. PubMed ID: 35187981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.